Related Experiment Video
Updated: Jan 24, 2026
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
Dual Antiplatelet Therapy beyond 1 Year after a Myocardial Infarction Compared with Low-Dose Aspirin Alone: A 3-Year
Patrick Blin1, Nicolas Danchin2, Jacques Benichou3
1Université de Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 33000, Bordeaux, France. patrick.blin@u-bordeaux.fr.
Introduction:
Antiplatelet therapy with low-dose aspirin, alone or as dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor, is used in secondary prevention following myocardial infarction (MI). However, the optimal duration of DAPT is unknown.
Methods:
This cohort study performed in the French nationwide claims database compared 3-year outcomes between DAPT and low-dose aspirin alone pursued beyond 1 year after MI. All adults discharged from hospital following MI in 2013-2014, and who survived ≥ 1 year under DAPT, without rehospitalization for acute coronary syndrome or major bleeding were enrolled (N = 51,468). The primary outcome was a composite of MI, stroke, major bleeding, or all-cause death during the 3 years following the index date (defined as 365 days after MI). Secondary outcomes were a composite of MI, stroke, and all-cause death, and each component of the primary composite. DAPT and low-dose aspirin exposure periods were analyzed as time-dependent variables and compared using hazard ratios (HR) from Cox proportional hazard or Fine-Gray competing risks models, adjusted using a high-dimensional disease risk score.
Results:
The 3-year cumulative follow-up duration was 93,398 person-years (DAPT exposure: 26,223 person-years; low-dose aspirin exposure: 67,175 person-years). HRs for DAPT versus low-dose aspirin were 0.93 (0.85-1.03) for the primary composite outcome, 0.93 (0.84-1.03) for the secondary composite outcome, 1.04 (0.87-1.25) for MI, 0.91 (0.70-1.17) for stroke, 1.19 (0.88-1.60) for major bleeding, and 0.94 (0.83-1.07) for death.
Conclusions:
This national cohort study did not find a significant benefit of continued DAPT beyond 1 year after MI compared with low-dose aspirin.
Registration:
This study was registered with the European Medicines Agency EUPASS registry ( https://catalogues.ema.europa.eu/catalogue-rwd-studies ; registration no. EUPAS29177).
Related Concept Videos
01:11Testing a Claim about Mean: Known Population SD
Estimating a population mean requires the samples to be distributed normally. The data should be collected from the randomly selected samples having no sampling bias. The sample size needed to be higher than 30, and most importantly, the population standard deviation should be already known.
In most realistic situations, the population standard deviation is often unknown, but in rare circumstances, when it...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
01:24Testing a Claim about Population Proportion
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
01:19Testing a Claim about Standard Deviation
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
01:21Testing a Claim about Mean: Unknown Population SD
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
01:21Dose Size and Dosing Frequency: Determination Methods